Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as B.1.1.7(the “British variant”), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University’s Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center.
The virus variant was labelled “Variant of Concern 202012/01” by Public Health England (PHE), an agency of the UK Department of Health and Social Care, in a publication… Read more
Northern Arizona University researchers Laura Foster Huenneke and Nancy Collins Johnson have been named Fellows of the American Association for the Advancement of Science (AAAS).
Scientists at two Northern Arizona University research centers—the 
One of the most challenging aspects of the COVID-19 pandemic has been the lack of testing needed to detect and trace infections—and without adequate testing, government officials do not have the data they need to make the best possible decisions in the interest of public health.